Medicare Coverage With Evidence Development Mandate Expires After Four Years Under Senate Bill

As CMS brings public attention to process with its national coverage analysis for Alzheimer’s drugs, legislation aims to encourage quick recommendations – and strengthen collaboration with FDA.